Core Viewpoint - Waters Corporation has successfully completed the combination with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions businesses, creating a global leader in life sciences and diagnostics with a strong financial outlook [1][3] Company Developments - The transaction has resulted in the formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences, focusing on high-volume testing in regulated applications and expansion into high-growth markets [5][6] - Claire M. Fraser, Ph.D., has been appointed to the Waters Board of Directors, bringing extensive experience in genomics and molecular diagnostics [2][3] Transaction Details - The combination was executed through a Reverse Morris Trust transaction, with Waters shareholders owning 60.8% and BD shareholders owning 39.2% of the combined company on a fully diluted basis [7] - BD shareholders will receive approximately 0.135 shares of Waters common stock for each share of BD common stock held as of February 5, 2026 [7] Strategic Focus - The company aims to address unmet customer needs, deliver long-term shareholder value, and provide solutions that advance global health through innovative products and a culture of innovation [3][9]